Iodine-125 brachytherapy and robotic stereotactic radiotherapy — treatment options for patients with localized prostate cancer

Introduction. Modern radiological treatment options for patients with localized prostate cancer (PCa) have several advantages and allow achieving high rates of biochemical control.

Purpose of the study. To compare immediate, proximate, and long-term results of low-dose Iodine-125 brachytherapy (I-125 BT) and robotic stereotactic radiotherapy (SBRT) in patients with localized low- and intermediate-risk PCa.

Materials and methods. The study included 296 patients with localized low- and intermediate-risk PCa. I-125 BT and SBRT were performed in 208 and 88 patients, respectively. All patients with an intermediate-risk PCa were prescribed neoadjuvant androgen-deprivation therapy (NADT) with luteinizing hormone-releasing hormone analogues (LHRH) for 4-6 months. Only radiation treatment was used for low-risk PCa. As a result, two groups and four subgroups of patients were formed depending on the treatment method. The immediate, proximate, and long-term results of radiation treatment methods were studied in groups and subgroups.

Results. No complications were recorded during brachytherapy I-125. Radiation cystitis grade 1 and radiation rectitis grade 1 were diagnosed after SBRT in 16.6% and 4.0% of cases, respectively. In the only I-125 BT subgroup, the PSA level during the year decreased from 8.3 to 1.1 ng/ml, in the SBRT subgroup — from 7.5 to 0.8 ng/ml. In the case of combined treatment, PSA decreased from 1.2 to 0.93 ng/ml and from 4.5 to 0.5 ng/ml, respectively. Changes in prostate volume, residual volume, and urinary quality (I-PSS) were comparable in all subgroups. Five-year cancer-specific survival and overall survival in the group of patients after SBRT was 100%, after I-125 BT — more than 90%.

Conclusion. Radiation treatment options for patients with localized PCa are safe. Conducting NADT does not significantly reduce the prostate volume and does not affect the indicators of urodynamics. High rates of cancer-specific five-year survival rate testify to the effectiveness of the evaluated treatment options.

1. Aoun F, Peltier A, van Velthoven R. A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer. Biomed Res Int. 2014; 2014:501213. DOI: 10.1155/2014/501213.

2. Garcia JR, Moreno C, Valls E, Cozar P, Bassa P, Soler M, Alvarez-Moro FJ, Moragas M, Riera E. Rendimiento diagnostico de la gammagrafta osea y la PET/TAC con (11)C-colina en la deteccion de metastasis oseas en pacientes con recidiva bioquimica de cancer de prostata [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer]. Rev Esp Med Nucl Ima-gen Mol. 2015;34 (3):155-61. (In Spanish). DOI: 10.1016/j.remn.2014.08.001.

3. Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Parker CC, Ritchie AW, Russell JM, Thalmann G, Cassoly E, Millman R, Matheson D, Schiavone F, Spears MR, Parmar MK, James ND. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol. 2014;66 (5):799-802. DOI: 10.1016/j.eururo.2014.05.038.

4. Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol. 2013;31 (4):455-60. DOI: 10.1016/j.urolonc.2011.02.023.

5. Vazhenin A. V., Karnaukh P.A. The Epidemiology of cancer of the prostate glands in the Chelyabinsk region. Palliative Medicine and Rehabilitation. 2008; (2):26-28. (In Russ.). eLIBRARY ID: 15120150.

6. Chissov V. I., Starinsky V. V., Petrova G. V., eds. Malignant neoplasms in Russia in 2009 (morbidity and mortality). Moscow; 2011. (In Russ.).

7. Kogan M. I., Pushkar D. U., eds. Prostate cancer: proteomics, genomics, surgery. Moscow; 2019. (In Russ.).

8. Chissov V. I., Starinsky V. V., Petrova G. V., eds. State of cancer care to the population of Russia in 2009. Moscow; 2010. (In Russ.).

9. Chissov V. I., Starinsky V. V., Petrova G. V., eds. The state of cancer care in Russia in 2009. Moscow: FGU «MNIOI P.A. Herzen Of Rosmedtechnologies»; 2011. (In Russ.).

10. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65 (1):124-37. DOI: 10.1016/j.eururo.2013.09.046.

11. James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, Ritchie AW, Russell JM, Schiavone F, Attard G, de Bono JS, Birtle A, Engeler DS, Elliott T, Matheson D, O'Sullivan J, Pudney D, Srihari N, Wallace J, Barber J, Syndikus I, Parmar MK, Sydes MR; STAMPEDE Investigators. Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA Oncol. 2016;2 (3):348-57. DOI: 10.1001/jama-oncol.2015.4350. Erratum in: JAMA Oncol. 2016;2 (2):279.

12. Tward JD, Kokeny KE, Shrieve DC. Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Pract Radiat Oncol. 2013;3 (3):234-240. DOI: 10.1016/j.prro.2012.11.011.

13. Zyryanov A. V., Bazhenov A.A., Mashkovtsev A. V. Brachytherapy in the treatment of patients with localized prostate cancer with benign prostatic hyperplasia. Ural medical journal. 2009; (11):35-36. (In Russ.).

14. Kaprin A. D., Ivanov S.A., Karyakin O. B., Obuhov A.A., Biryukov V.A., Borysheva N. B., Sanin D. B., Lepilina O. G., Smolkin A. L., Dem'yanovich A. V., Minaeva N. G., Mikhay-lovskiy N. V. Salvage high-doserate brachytherapy for recurrent prostate cancer. Cancer Urology. 2020;16 (4):112-119. (In Russ.). DOI: 10.17650/1726-9776-2020-16-4-112-119

15. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004;58 (1):3-10. DOI: 10.1016/s0360-3016(03)01442-1.

16. Lin CC, Gray PJ, Jemal A, Efstathiou JA. Androgen deprivation with or without radiation therapy for clinically nodepositive prostate cancer. J Natl Cancer Inst. 2015;107 (7): djv119. DOI: 10.1093/jnci/djv119.

17. Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2014;88 (5):1064-73. DOI: 10.1016/j.ijrobp.2014.01.008.

18. Gabriele D, Collura D, Oderda M, Stura I, Fiorito C, Porpiglia F, Terrone C, Zacchero M, Guiot C, Gabriele P. Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database. World J Urol. 2016;34 (4):517-23. DOI: 10.1007/s00345-015-1669-2.

19. Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, Madan RA, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL. Prospective Study Evaluating Na18F PET/CT in Predicting -Clinical Outcomes and Survival in Advanced Prostate Cancer. J Nucl Med. 2016;57 (6):886-92. DOI: 10.2967/jnumed.115.166512.

20. von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun. 2014;35 (3):221-30. DOI: 10.1097/MNM.0000000000000040.

21. van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117 (5):732-9. DOI: 10.1111/bju.13397.

22. Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13 (4):226-35. DOI: 10.1038/nrurol.2016.26.

23. Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol. 2016;70 (1):161-175. DOI: 10.1016/j.eururo.2016.01.029.

24. Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol. 2014; 4:240. DOI: 10.3389/fonc.2014.00240.

25. Sanfilippo NJ, Cooper BT. Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations. Am J Clin Exp Urol. 2014;2 (4):286-93. PMID: 25606574; PMCID: PMC4297324.

26. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M 3rd, Briganti A. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67 (5):852-63. DOI: 10.1016/j.eururo.2014.09.004.

27. Cho SY, Szabo Z. Molecular imaging of urogenital diseases. Semin Nucl Med. 2014;44 (2):93-109. DOI: 10.1053/j.sem-nuclmed.2013.10.008.